Day: November 12, 2024

Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update

Written by Customer Service on November 12, 2024. Posted in Public Companies.

Company accelerated commercialization with significant new partnerships both in the U.S. and Europe ATLANTA, Nov. 12, 2024 (GLOBE NEWSWIRE) — Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces financial results for the quarter ended September 30, 2024 and provides a corporate update. Corporate Highlights from 3Q 2024 to dateAnnounced partnership with Boston IVF, prominent network of fertility centers, to offer FemaSeed® Announced the onboarding of the first infertility medical clinic customers to offer FemaSeed infertility treatment to patients in California and Florida Announced strategic distribution partnerships for CE-marked products, including...

NY Times Best Selling Author and Reality Television Personality Stassi Schroeder Moves Stassi Podcast to PodcastOne (PODC) in Seven Figure Deal

Written by Customer Service on November 12, 2024. Posted in Public Companies.

Stassi Move Strengthens Platform’s Existing Female-Focused Slate of Programming 49th New Podcast Joining PodcastOne’s Platform in 2024, 189 Total Podcasts LOS ANGELES, Nov. 12, 2024 (GLOBE NEWSWIRE) — PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), announced today the acquisition of the highly acclaimed Stassi podcast, hosted by bestselling author and reality television personality Stassi Schroeder in a multiyear seven figure deal. The podcast addition strengthens and grows PodcastOne’s existing commitment to providing engaging content tailored to women. On the Stassi podcast, Stassi shares candid stories, personal reflections, and her token commentary on everything from pop culture to relationships to style, and beyond. With each episode, listeners get an intimate glimpse...

AXIL Brands Launches ‘X Series’ Earplugs: The Ultimate Fusion of Design, Fit, and Performance

Written by Customer Service on November 12, 2024. Posted in Public Companies.

LOS ANGELES, Nov. 12, 2024 (GLOBE NEWSWIRE) — (GLOBE NEWSWIRE) – AXIL Brands, Inc. (“AXIL” or the “Company”) (NYSE American: AXIL), an emerging global consumer products company for AXIL® hearing protection and enhancement products and Reviv3® hair and skin care products, announces the launch of its latest innovation, the ‘X Series’ Earplugs. The ‘X Series’ is engineered to provide an unparalleled hearing protection experience while delivering comfort and style. It is designed for multi-faceted lifestyles where hearing protection is needed or the ability to maintain hearing while simultaneously protecting one’s hearing is needed. X Series earplugs will provide hearing protection for various lifestyles and activities, such as motorsports, concert goers, stadium events, sleeping, auditory overload sensitivity, air travel, hunting,...

Foresight Launches Six Advanced Stereoscopic Sensor Kits to Revolutionize Industrial and Automotive 3D Perception

Written by Customer Service on November 12, 2024. Posted in Public Companies.

Foresight’s new sensor kit portfolio, designed for serial production, empowers developers and manufacturers across diverse sectors, including automated special purpose vehicles, warehouse and logistics automation, drones, unmanned aerial vehicles, aviation, and autonomous vehicle applications. Ness Ziona, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) — Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX) (“Foresight” or the “Company”), an innovator in automotive vision systems, announced the launch of its advanced sensor kit portfolio: ScaleCam™ Vision, ScaleCam™ Thermal, and QuadSight® in various configurations. These cutting-edge sensor kits are engineered to enhance perception capabilities, meeting the stringent requirements for applications in industrial automation and autonomous mobility. We believe that this...

Dime Community Bancshares Announces Pricing of Common Stock Offering

Written by Customer Service on November 12, 2024. Posted in Public Companies.

HAUPPAUGE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) — Dime Community Bancshares, Inc. (Nasdaq: DCOM) (“Dime” or the “Company”), the parent company of Dime Community Bank, announced the pricing of a public offering of 3,906,250 shares of its common stock, $0.01 par value (the “Common Stock”), at a public offering price of $32.00 per share, for aggregate gross proceeds of $125 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 585,937 shares of Common Stock at the public offering price, less underwriting discounts and commissions. The Company expects to close the offering, subject to customary conditions, on or about November 13, 2024. Dime expects to use the net proceeds from this offering for general corporate purposes to support its continued organic growth, which may include,...

Navient Receives Champion of Board Diversity Recognition by The Forum of Executive Women

Written by Customer Service on November 12, 2024. Posted in Public Companies.

HERNDON, Va., Nov. 12, 2024 (GLOBE NEWSWIRE) — Navient (Nasdaq: NAVI) has been recognized by The Forum of Executive Women as a Champion of Board Diversity. This award annually honors the top public companies in the Philadelphia region with boards comprised of at least 30% women. The Forum of Executive Women’s annual Women in Leadership Report, which will be released in November and is a collaboration with PwC, provides an annual examination on diversity in the boardrooms and executive suites of the top 100 public companies in the Philadelphia region. This year, a record number of Champions of Board Diversity will be recognized — with 46 companies receiving the designation, up from 37 organizations in the year prior. The Champions of Board Diversity will be celebrated at an event today, featuring a keynote by Mary Purk,...

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on November 12, 2024. Posted in Public Companies.

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences: Jefferies London Healthcare Conference (London, UK)Management will participate in one-on-one meetings from Tuesday, November 19th through Thursday, November 21st, 2024. Piper Sandler 36th Annual Healthcare Conference (New York, NY)Management is scheduled to participate in a fireside chat on Tuesday, December 3rd, 2024 at 3:30pm ET and will participate in one-on-one meetings. 7th Annual Evercore HealthCONx Conference (Coral...

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Written by Customer Service on November 12, 2024. Posted in Public Companies.

Proceeds from the full exercise of warrants issued in the first quarter of 2024 private placement bring the total gross proceeds from the transaction to $185 million Cash runway expected into at least 2027WAYNE, Pa. and ROCKVILLE, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that it has received $69.4 million in gross proceeds from the full exercise of the warrants issued in a March 2024 private placement. “We appreciate the outstanding support of our investors by fully exercising their warrants from the private placement earlier this year. While our primary focus remains on the execution of our Phase 2 LOTUS trial in hidradenitis suppurativa, we are excited to expand the AVTX-009 program...

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on November 12, 2024. Posted in Earnings Releases And Operating Results.

Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer’s disease agitation with data expected in second half of 2025 Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025 Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026 Conference call today at 8:00am ET WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced...

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

Written by Customer Service on November 12, 2024. Posted in Earnings Releases And Operating Results.

– EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU– Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO– Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination– Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number of impactful portfolio milestones WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 12, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results...

Day: November 12, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice